TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30907130

Group type: EXPERIMENTAL
Intervention: Preoperative multimedia-based nursing visit
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (no multimedia-based nursing visit)
Number of subjects: 128
Study: 27503364

Group type: EXPERIMENTAL
Intervention: Regular grapefruit juice (RGJ)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low-furanocoumarin hybrid grapefruit juice (HGJ)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study: 25162304

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention with four home visits over four months.
Number of subjects: 101

Group type: COMPARATOR
Intervention: Attention control arm receiving four newsletters covering the same topics.
Number of subjects: 101
Study: 23820927

Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 21614811

Group type: EXPERIMENTAL
Intervention: HPV detection and genotyping using PCR‐SPF10/LiPA (INNOLiPA Extra Amp)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: p16INK4a immunodetection using antibody clone E6H4
Number of subjects: 67
Study: 19627683

Group type: EXPERIMENTAL
Intervention: Videotape of exercises and instructions to support routine physiotherapy consultations
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Videotape of exercises and instructions
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Videotape of exercises
Number of subjects: 33
Study: 16886585

Group type: EXPERIMENTAL
Intervention: High-fat meal before exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo before exercise
Number of subjects: 12
Study: 15579798

Group type: EXPERIMENTAL
Intervention: 1 mg recombinant human GHRH-1,44-amide s.c. twice daily for 3 months
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 4 mg recombinant human GHRH-1,44-amide s.c. twice daily for 3 months
Number of subjects: 22
Study: 11603848

Group type: EXPERIMENTAL
Intervention: freeze-dried U guianensis
Number of subjects: 45

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 45
Study: 9821760

Group type: EXPERIMENTAL
Intervention: Brief intervention by primary care physicians with feedback and monitoring of symptoms and clinical findings including biochemical markers; self-help pamphlet recommended.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of serum gamma‐glutamyl transpeptidase (GGT) level as a biochemical marker.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-judgmental lifestyle approach to define problems in terms of lifestyle habits and consequences.
Number of subjects: 0
Study: 8123837

Group type: EXPERIMENTAL
Intervention: Ki-67 monoclonal antibody (MoAb) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low proliferative index
Number of subjects: 0

Group type: COMPARATOR
Intervention: High proliferative index
Number of subjects: 0
Study: 2523661

Group type: EXPERIMENTAL
Intervention: Isradipine (0.6 microgram/kg/minute, decreasing to 0.3 microgram/kg/minute)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nitroprusside (1 microgram/kg/minute)
Number of subjects: 20
Study: 331835

Group type: EXPERIMENTAL
Intervention: Oxprenolol (80 mg three times a day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31521543

Group type: EXPERIMENTAL
Intervention: High frequency left sided rTMS (125 trains per day)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Standard left sided rTMS (50 trains per day)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Standard right sided rTMS (20 min per day)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: High right sided rTMS (60 min per day)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: High left sided treatment
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 300
Study: 30649163

Group type: EXPERIMENTAL
Intervention: SQ-LNS-plus
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: SQ-LNS
Number of subjects: 750

Group type: COMPARATOR
Intervention: Control (no supplement)
Number of subjects: 750
Study: 27280511

Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 505

Group type: COMPARATOR
Intervention: Spleen preservation
Number of subjects: 505
Study: 25455414

Group type: EXPERIMENTAL
Intervention: 600 mg/kg iodine load and 120 kVp tube voltage setting (600-120 group)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 500 mg/kg iodine load and 80 kVp (500-80 group)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 400 mg/kg iodine load and 80 kVp (400-80 group)
Number of subjects: 170

Group type: COMPARATOR
Intervention: All groups (600-120, 500-80, 400-80)
Number of subjects: 170
Study: 24332551

Group type: EXPERIMENTAL
Intervention: Harmonic ACE scalpel (HS)
Number of subjects: 832

Group type: COMPARATOR
Intervention: LigaSure Precise (LS) instrument
Number of subjects: 832
Study: 23177745

Group type: EXPERIMENTAL
Intervention: Resonant voice (RV) exercises
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Voice rest
Number of subjects: 9

Group type: COMPARATOR
Intervention: Spontaneous speech (SS)
Number of subjects: 9
Study: 20009911

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (PCb)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GC)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Vinorelbine plus cisplatin (VC)
Number of subjects: 607
Study: 17702881

Group type: EXPERIMENTAL
Intervention: PEPA intervention
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 48
Study: 15165935

Group type: EXPERIMENTAL
Intervention: Tezosentan (endothelin receptor antagonist)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 11524895

Group type: EXPERIMENTAL
Intervention: Day treatment programs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parental involvement in therapy
Number of subjects: 0
Study: 8986944

Group type: EXPERIMENTAL
Intervention: Prolonged therapy group (5 MU tiw for a further 26 weeks)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Brief therapy group (stopped interferon)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Prolonged therapy group
Number of subjects: 310

Group type: COMPARATOR
Intervention: Brief therapy group
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Overall sustained biochemical response
Number of subjects: 310
Study: 8247317

Group type: EXPERIMENTAL
Intervention: tolrestat (aldose reductase inhibitor)
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study: 3621990

Group type: EXPERIMENTAL
Intervention: 100 mg spironolactone
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 27638453

Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 374

Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 374
Study: 26725101

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 44
Study: 24916511

Group type: EXPERIMENTAL
Intervention: New Beginnings Program (NBP)
Number of subjects: 240
Study: 21544086

Group type: EXPERIMENTAL
Intervention: 8-week dietary intervention
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 8-week dietary intervention (A142V polymorphism CC and CT group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 8-week dietary intervention (R65L polymorphism GG and GT group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard diet (control group)
Number of subjects: 80
Study: 20536757

Group type: EXPERIMENTAL
Intervention: Telephone counseling for patients after surgery
Number of subjects: 174
Study: 18178011

Group type: EXPERIMENTAL
Intervention: Therapeutic Interactive Voice Response (TIVR) for 4 months
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard care only (Control)
Number of subjects: 51
Study: 16686000

Group type: EXPERIMENTAL
Intervention: Robotic needle placement for radio-frequency ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual needle placement for radio-frequency ablation
Number of subjects: 0
Study: 12514146

Group type: EXPERIMENTAL
Intervention: Sevoflurane 2% with propofol 2 mg x kg(‐1) (Group I)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% (Group II)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sevoflurane with gradual reduction technique (8, 6, 4% for each minute) (Group III)
Number of subjects: 45
Study: 10393599

Group type: EXPERIMENTAL
Intervention: 6 to 10 puffs of albuterol via MDI with spacer (n = 30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 2 puffs of albuterol via MDI with spacer (n = 30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg of albuterol via nebulizer (n = 30)
Number of subjects: 90
Study: 9715320

Group type: EXPERIMENTAL
Intervention: Treatment with antibiotics
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Increase in storage time
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Methyl thiazol tetrazolium (MTT) assay
Number of subjects: 104

Group type: COMPARATOR
Intervention: Basal media with and without nutrients (DMEM and Hanks BSS)
Number of subjects: 104
Study: 1560152

Group type: EXPERIMENTAL
Intervention: Iontophoresis of lidocaine HCl 4%
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Iontophoresis of lidocaine HCl 4% with epinephrine 1:50,000
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 11
Study: 2865145

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg eight-hourly
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study: 29722627

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot supplementation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nitrate-poor (placebo) beetroot supplementation
Number of subjects: 9
Study: 27491658

Group type: EXPERIMENTAL
Intervention: Standard procedure with balloon predilatation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Omitted balloon predilatation
Number of subjects: 60
Study: 26047635

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 16
Study: 23611518

Group type: EXPERIMENTAL
Intervention: Intensified regimen of enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard regimen of enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 128
Study: 21044299

Group type: EXPERIMENTAL
Intervention: COPCA (Coping with and Caring for infants with special needs ‐ a family centered program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional infant physiotherapy
Number of subjects: 0
Study: 19317161

Group type: EXPERIMENTAL
Intervention: Yiqi Wenyang Huoxue Recipe (YWHR) given daily for 10 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Yiqi Wenyang Huoxue Recipe (YWHR)
Number of subjects: 60
Study: 16640636

Group type: EXPERIMENTAL
Intervention: Thermafil system (G3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: System B (G2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lateral condensation (G1)
Number of subjects: 60
Study: 14502777

Group type: EXPERIMENTAL
Intervention: Breast conservation therapy (BCT)
Number of subjects: 928

Group type: COMPARATOR
Intervention: Mastectomy (Mx)
Number of subjects: 928
Study: 10850507

Group type: EXPERIMENTAL
Intervention: Prophylactic indomethacin (0.1 mg/kg, administered within the first 24 hours of life, repeated every 24 hours for 6 doses)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (administered within the first 24 hours of life, repeated every 24 hours for 6 doses)
Number of subjects: 90
Study: 8791036

Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/day
Number of subjects: 55

Group type: COMPARATOR
Intervention: Clomipramine 150 mg/day
Number of subjects: 55
Study: 1361781

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 25 mg/l during four short dwell exchanges (dwell time 1.5 h)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 100 mg/l in the last-bag
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 25 mg/l in the last-bag
Number of subjects: 6

Group type: COMPARATOR
Intervention: No ciprofloxacin during four subsequent 1.5h exchanges
Number of subjects: 6
Study: 6368563

Group type: EXPERIMENTAL
Intervention: Operative repair
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conservative treatment in a plaster cast
Number of subjects: 100
Study: 31494621

Group type: EXPERIMENTAL
Intervention: Antibiotics (specific type and dosage not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29214507

Group type: EXPERIMENTAL
Intervention: Bemiparin once daily
Number of subjects: 312

Group type: COMPARATOR
Intervention: Enoxaparin twice daily
Number of subjects: 312
Study: 26421801

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 125

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 125
Study: 24689456

Group type: EXPERIMENTAL
Intervention: Gluten (16 g/day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Whey (16 g/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (not supplemented)
Number of subjects: 22
Study: 22318363

Group type: EXPERIMENTAL
Intervention: Prismatic lenses producing a deviation of 5 degrees to the right
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pointing exercises
Number of subjects: 29

Group type: COMPARATOR
Intervention: Neutral lenses (placebo)
Number of subjects: 29
Study: 20624011

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg p.o. bi-daily for 4 months)
Number of subjects: 22
Study: 17711996

Group type: COMPARATOR
Intervention: GLP-1 with placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: GLP-1 with glyburide
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: GLP-1 with glimepiride
Number of subjects: 29
Study: 16291352

Group type: EXPERIMENTAL
Intervention: Clinical pathway for management of bronchiolitis
Number of subjects: 436
Study: 12400431

Group type: EXPERIMENTAL
Intervention: Acupuncture and oral administration of Huo Xue Ming Mu Decoction
Number of subjects: 32
Study: 9952267

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT) monotherapy
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Polytherapy (more than one AED)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Sodium Valproate (VPA)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Sexuality Experience Scores (SES)
Number of subjects: 184
Study: 8649918

Group type: EXPERIMENTAL
Intervention: 0 degree rotation
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: randomized neck rotation positions
Number of subjects: 17
Study: 1857134

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 6407052

Group type: EXPERIMENTAL
Intervention: Fusaric acid plus L-dopa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-dopa alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30403402

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil extended-release (GE-XR) 600 mg twice a day
Number of subjects: 346

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346
Study: 29729860

Group type: EXPERIMENTAL
Intervention: Ventilatory therapy combined with exercise training (V+ET)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Exercise training alone (ET)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Ventilatory therapy combined with exercise training (V+ET) in subjects with central sleep apnoea (CSA)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Exercise training alone (ET) in subjects with central sleep apnoea (CSA)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Exercise training alone (ET) in subjects with obstructive sleep apnoea (OSA)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Ventilatory therapy combined with exercise training (V+ET) in subjects with obstructive sleep apnoea (OSA)
Number of subjects: 118
Study: 27103201

Group type: EXPERIMENTAL
Intervention: Vitamin D-binding protein
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D (25-OH D)
Number of subjects: 333
Study: 24509716

Group type: EXPERIMENTAL
Intervention: Baseline PET/CT imaging
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Baseline and 6-week PET/CT imaging
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Baseline and 12-week PET/CT imaging
Number of subjects: 99
Study: 22228539

Group type: COMPARATOR
Intervention: 453 g concentrate (T1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 342 g concentrate + 74 g lupin seed (T2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 228 g concentrate + 147 g lupin seed (T3)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 116 g concentrate + 219 g lupin seed (T4)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 290 g lupin seed (T5)
Number of subjects: 30
Study: 19737630

Group type: EXPERIMENTAL
Intervention: Increased GI (iGI) variants
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Decreased GI (dGI) variants
Number of subjects: 40

Group type: COMPARATOR
Intervention: Reference solution (glucose solution)
Number of subjects: 40
Study: 17517820

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (specific medications not detailed)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 415

Group type: COMPARATOR
Intervention: No pharmacotherapy (Control)
Number of subjects: 415
Study: 16390022

Group type: EXPERIMENTAL
Intervention: 99mTc(V)-DMSA scan
Number of subjects: 28

Group type: COMPARATOR
Intervention: 99mTc-MDP scan
Number of subjects: 28

Group type: COMPARATOR
Intervention: CT scan
Number of subjects: 28
Study: 12589270

Group type: EXPERIMENTAL
Intervention: Pedal unit position behind the saddle axis
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pedal unit position in front of the saddle axis
Number of subjects: 10
Study: 10604698

Group type: EXPERIMENTAL
Intervention: Burch retropubic urethropexy
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Modified Pereyra procedure
Number of subjects: 289

Group type: COMPARATOR
Intervention: Anterior repair
Number of subjects: 289
Study: 8540119

Group type: EXPERIMENTAL
Intervention: Cisplatin high dose (100 mg/m2 i.v. day 1) + Etoposide (100 mg/m2 i.v. days 4, 6, and 8)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Cisplatin low dose (60 mg/m2 day 1) + Etoposide (100 mg/m2 i.v. days 4, 6, and 8)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Cisplatin high dose (100 mg/m2 i.v. day 1)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Cisplatin low dose (60 mg/m2 day 1)
Number of subjects: 95
Study: 2312831

Group type: EXPERIMENTAL
Intervention: SPF-30 sunscreen
Number of subjects: 0

Group type: COMPARATOR
Intervention: SPF-15 sunscreen
Number of subjects: 0
Study: 7002357

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfinpyrazone
Number of subjects: 0
Study: 30428398

Group type: COMPARATOR
Intervention: PCI with sirolimus-eluting or paclitaxel-eluting stents
Number of subjects: 943

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 943
Study: 27809622

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate plus isosorbide mononitrate 10 mg vaginal tablets
Number of subjects: 120

Group type: COMPARATOR
Intervention: Clomiphene citrate 100 mg daily plus placebo vaginal tablets
Number of subjects: 120
Study: 25165161

Group type: EXPERIMENTAL
Intervention: Inactivated Influenza Vaccine (IIV) followed by Live Attenuated Influenza Vaccine (LAIV)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine (LAIV) followed by Live Attenuated Influenza Vaccine (LAIV)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Initial dose of Live Attenuated Influenza Vaccine (LAIV)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Inactivated Influenza Vaccine (IIV)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Live Attenuated Influenza Vaccine (LAIV)
Number of subjects: 39
Study: 24991557

Group type: EXPERIMENTAL
Intervention: Feedback-mediated exercise (FME)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No-feedback exercise (NFE)
Number of subjects: 20
Study: 22130166

Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipilimumab and vaccine
Number of subjects: 0
Study: 19625327

Group type: EXPERIMENTAL
Intervention: Surgical treatment for mixed urinary incontinence (MUI)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nonsurgical treatment for mixed urinary incontinence (MUI)
Number of subjects: 27
Study: 17565782

Group type: EXPERIMENTAL
Intervention: Contact with wild representation (monkey or clothed dog)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Gadje majority)
Number of subjects: 0
Study: 15023191

Group type: EXPERIMENTAL
Intervention: Advice to eat more fatty fish
Number of subjects: 3114

Group type: EXPERIMENTAL
Intervention: Advice to eat more fruit and vegetables
Number of subjects: 3114
Study: 11847990

Group type: EXPERIMENTAL
Intervention: Breastfeeding education session
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (received session after posttest)
Number of subjects: 0
Study: 9747834

Group type: COMPARATOR
Intervention: 4 Gy
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: 6 Gy
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: 8 Gy
Number of subjects: 327
Study: 8150304

Group type: EXPERIMENTAL
Intervention: Falls prevention program addressing home safety, exercise, and behavioral risks
Number of subjects: 3182
Study: 3255829

Group type: EXPERIMENTAL
Intervention: 400 mg trimethoprim
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 200 mg trimethoprim
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 100 mg trimethoprim
Number of subjects: 3

Group type: COMPARATOR
Intervention: Conventional treatment (5-7 days)
Number of subjects: 3
Study: 28287005

Group type: EXPERIMENTAL
Intervention: Music intervention during NST
Number of subjects: 409

Group type: COMPARATOR
Intervention: No music intervention during NST
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 409
Study: 27330977

Group type: EXPERIMENTAL
Intervention: 1 mg risperidone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21